Phase II Trial of Irinotecan plus Cisplatin Combination as First Line Therapy for Patients with Small cell Lung Cancer |
Jeong, Hye Cheol
(Department of Internal Medicine, College of Medicine, Korea University)
Lee, Sang Yeub (Department of Internal Medicine, College of Medicine, Korea University) Kim, Jung Ha (Department of Internal Medicine, College of Medicine, Korea University) Ha, Eun Sil (Department of Internal Medicine, College of Medicine, Korea University) Jung, Jin Yong (Department of Internal Medicine, College of Medicine, Korea University) Lee, Kyung Ju (Department of Internal Medicine, College of Medicine, Korea University) Lee, Seung Hyeun (Department of Internal Medicine, College of Medicine, Korea University) Kim, Se Joong (Department of Internal Medicine, College of Medicine, Korea University) Lee, Eun Joo (Department of Internal Medicine, College of Medicine, Korea University) Hur, Gyu Young (Department of Internal Medicine, College of Medicine, Korea University) Lee, Sung Yong (Department of Internal Medicine, College of Medicine, Korea University) Kim, Je Hyeong (Department of Internal Medicine, College of Medicine, Korea University) Shin, Chol (Department of Internal Medicine, College of Medicine, Korea University) Shim, Jae Jeong (Department of Internal Medicine, College of Medicine, Korea University) In, Kwang Ho (Department of Internal Medicine, College of Medicine, Korea University) Kang, Kyung Ho (Department of Internal Medicine, College of Medicine, Korea University) Yoo, Se Hwa (Department of Internal Medicine, College of Medicine, Korea University) |
1 | Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev 2004;30:521-43 DOI ScienceOn |
2 | World Health Organization. WHO Handbook for Results of Cancer Treatment: WHO offset Publication No. 48. Geneva, Switzerland, Word Health Organization, 1979 |
3 | Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004;22:4785-93 |
4 | Mitsuoka S, Kudoh S, Takada Y. Phase II study of cisplatin, etoposide and concurrent thoracic radiotherapy (TRT) followed by irinotecan and cisplatin in patients with limited stage small-cell lung cancer (SCLC); updated results of WJTOG 9902, Proc Am Soc Clin Oncol. 2004;23:624a |
5 | Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998;16:1068-74 DOI |
6 | Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91 DOI ScienceOn |
7 | Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol. 2005;23:3488-94 DOI ScienceOn |
8 | Stuschke M, Pottgen C. Localized small-cell lung cancer: which type of thoracic radiotherapy and which time schedule. Lung Cancer 2004;45:133-7 DOI ScienceOn |
9 | Oka M, Fukuda M, Kuba M, Ichiki M, Rikimaru T, Soda H, et al. Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer. Eur J Cancer 2002;38:1998-2004 DOI ScienceOn |
10 | Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama T, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7 DOI |
11 | Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004;49:119-33 DOI ScienceOn |